Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
Open Access
- 15 January 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (2), 813
- https://doi.org/10.3390/ijms22020813
Abstract
Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets.This publication has 102 references indexed in Scilit:
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue SarcomasJournal of Clinical Oncology, 2012
- The Molecular Pathogenesis of Osteosarcoma: A ReviewSarcoma, 2011
- Addition of pamidronate to chemotherapy for the treatment of osteosarcomaCancer, 2010
- Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cellsMolecular Cancer, 2010
- Oleanolic acid derivative Dex-OA has potent anti-tumor and anti-metastatic activity on osteosarcoma cells in vitro and in vivoInvestigational New Drugs, 2009
- Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulationBritish Journal of Cancer, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Hedgehog: functions and mechanismsGenes & Development, 2008
- Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sproutingProceedings of the National Academy of Sciences of the United States of America, 2007
- Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesisExperimental Cell Research, 2006